latest news releases from the newsroom
The Savannah Bancorp, Inc.
Savannah Bancorp Reports First Quarter Earnings and Declares Regular Quarterly Dividend
SAVANNAH, Ga., April 22, 2008 (PRIME NEWSWIRE) -- The Savannah Bancorp, Inc. (Nasdaq:SAVB) reported net income for the first quarter 2008 of $1,704,000 compared to $2,311,000 in the first quarter 2007. Net income per diluted share was 29 cents compared to 39 cents per diluted share in the first quarter of 2007, a decrease of 26 percent. The decline in first quarter earnings results primarily from a higher provision for loan losses and a lower net interest margin in 2008 as compared to 2007.
Oriens Travel & Hotel Management Corp.
Oriens Offers $1 Dream Vacations at eBay
LAS VEGAS, April 22, 2008 (PRIME NEWSWIRE) -- Oriens Travel & Hotel Management Corp. ("Oriens") (Other OTC:OTHM) (http://www.orienscorp.com), an emerging Travel and Hotel Management Company operating online travel booking site 128trip (http://www.128trip.com) and hotel management subsidiary Hotel PURE (http://www.HotelPURE.com), is pleased to announce that Hotel PURE properties in the Central America region are now available on eBay.
Beacon Enterprise Solutions Group, Inc.
Beacon Solutions Names Paul D. Carlisle as Director of Network Services
LOUISVILLE, Ky.; CINCINNATI and COLUMBUS, Ohio, April 22, 2008 (PRIME NEWSWIRE) -- Beacon Enterprise Solutions Group, Inc. (OTCBB:BEAC) today announced that the Company has tapped regional telecommunications executive Paul D. Carlisle to serve as the Company's Director of Network Services.
Taro Pharmaceutical Industries Ltd.
Taro Receives Final FDA Approval for Cetirizine Hydrochloride Oral Solution ANDA
HAWTHORNE, N.Y., April 22, 2008 (PRIME NEWSWIRE) -- Taro Pharmaceutical Industries Ltd. (Pink Sheets:TAROF) ("Taro", the "Company") reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride oral solution, 1 mg / 1 mL ("Cetirizine Oral Solution"). The product will be marketed by Taro's U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.